A panel of serum biomarkers, including dietary and microbial-derived metabolites related to the gut-brain axis, were identified as potential for tracking children at risk of early childhood developmental delays.

FMT alleviated the intestinal barrier damage caused by enterotoxigenic Escherichia coli infection in antibiotic-induced microbiome-disordered model through increasing the relative abundance of A. muciniphila in the intestine.

Gut microbiota from young mice can alleviate gout and hyperuricemia in aged mice, further revealing that the metabolic product butyrate derived from the gut microbiota exerts similar therapeutic effects.